Senior insider sale
Chief Scientific Officer at ZENTALIS PHARMACEUTICALS, INC. — senior position signals high conviction
$38.4K
18.78K shares
What this filing means
LACKNER MARK plans to sell 18.78K shares of ZENTALIS PHARMACEUTICALS, INC. valued at approximately $38.4K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/3/2025ACC: 0001725160-25-000022
Officer· Chief Scientific Officer
Since Dec 2023
18.78K
Shares to sell
$38.4K
Approx. market value
14.37K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted Stock Unit Release
NA
2/1/2025
14.37KTotal acquired14.37K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/1/2025 | Restricted Stock Unit Release NA | 14.37K | — |
| Total | 14.37K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
4.41K
Market value
$13.8K
1/2/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
14.37K
Market value
$24.6K
2/3/2025
Total
Units
18.78K
Value
$38.4K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
1/2/2025 | 4.41K | $13.8K | — | Completed |
| Planned — Approximate Date | ||||
2/3/2025 | 14.37K | $24.6K | NASDAQ | Planned |
| Total | 18.78K | $38.4K | ||